articleThe LancetJun 25, 2023Closed access

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

FKFilip K. KnopVRVanita R. ArodaRDRuben D do ValeTHThomas Holst‐HansenPNPeter Nørkjær Laursen

University of Copenhagen · Gentofte Hospital · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

366
total citations
FWCI
65.39
Percentile
100%
References
38
Citations per year

Authors

8

Topics & keywords

Topics
Keywords
  • Semaglutide
  • Placebo
  • Overweight
  • Medicine
  • Obesity
  • Double blind
  • Randomized controlled trial
  • Physical therapy
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding